Genmab A/S (GMAB) News Today $33.17 +0.42 (+1.28%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$33.41 +0.24 (+0.72%) As of 10/17/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Genmab A/S Up Today?Toggle Visibility of Why Is Genmab A/S Up Today?Genmab A/S (NASDAQ:GMAB) shares are trading higher today after the stock hit a new 1‑year high and analysts continue to show overall conviction, but the move is being balanced by fresh downward FY2026 estimate revisions and a notable rise in short interest. Below are the key items investors should know and how they may influence the share price. Positive Sentiment: Stock set a new 1‑year high, signaling strong buying momentum and technical interest that can attract momentum traders. Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High - What's Next? Positive Sentiment: HC Wainwright continues to carry a Buy rating with a $40 target and issued upgrades to some near-term 2025 estimates (supporting sentiment that near‑term fundamentals look stronger). What is HC Wainwright's Estimate for Genmab A/S Q3 Earnings? Neutral Sentiment: Consensus from brokers is a "Moderate Buy" (11 analysts), which supports demand but leaves room for differing views and volatility around guidance and pipeline news. Genmab Receives Average Recommendation of "Moderate Buy" Negative Sentiment: HC Wainwright cut Q2–Q4 and FY2026 EPS forecasts (reducing FY2026 from $2.38 to $2.26), which introduces earnings risk for 2026 and could cap upside until guidance clarity arrives. HC Wainwright Has Negative Outlook of Genmab A/S Q2 Earnings Negative Sentiment: Leerink/others trimmed FY2026 EPS estimates, signaling some analyst concern about next‑year growth and potentially pressuring multiple expansion. FY2026 EPS Estimates for Genmab A/S Cut by Leerink Partners Negative Sentiment: Short interest jumped ~59% in September to ~5.56M shares (≈0.9% of float), raising the potential for near‑term volatility — both downside pressure from short selling and squeeze risk if positive catalysts continue. Posted 1+ days agoAI Generated. May Contain Errors. GMAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Vanguard Personalized Indexing Management LLC Has $1.09 Million Position in Genmab A/S Sponsored ADR $GMABOctober 19 at 3:34 AM | marketbeat.comWhat is HC Wainwright's Estimate for Genmab A/S Q2 Earnings?October 19 at 2:57 AM | americanbankingnews.comGenmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial CancerOctober 18 at 6:00 AM | businesswire.comGenmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial CancerOctober 18 at 6:00 AM | globenewswire.comWall Street Zen Downgrades Genmab A/S (NASDAQ:GMAB) to BuyOctober 18 at 2:42 AM | marketbeat.comWhat is HC Wainwright's Forecast for Genmab A/S Q3 Earnings?October 18 at 2:39 AM | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Hits New 1-Year High - What's Next?October 17 at 12:55 PM | marketbeat.comHC Wainwright Has Negative Outlook of Genmab A/S Q2 EarningsOctober 17 at 6:38 AM | marketbeat.comFY2026 EPS Estimates for Genmab A/S Cut by Leerink PartnrsOctober 17 at 2:59 AM | americanbankingnews.comWhat is HC Wainwright's Estimate for Genmab A/S Q3 Earnings?October 16 at 7:14 AM | marketbeat.comUS Bancorp DE Has $1.82 Million Stock Holdings in Genmab A/S Sponsored ADR $GMABOctober 16 at 3:25 AM | marketbeat.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 16 at 2:57 AM | americanbankingnews.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 16 at 2:23 AM | marketbeat.comGenmab A/S (NASDAQ:GMAB) Earns Buy Rating from HC WainwrightOctober 15, 2025 | marketbeat.comLeerink Partnrs Reduces Earnings Estimates for Genmab A/SOctober 15, 2025 | marketbeat.comQ3 EPS Estimates for Genmab A/S Lowered by Leerink PartnrsOctober 14, 2025 | marketbeat.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025October 14, 2025 | globenewswire.com31,681 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by Callan Family Office LLCOctober 14, 2025 | marketbeat.comGenmab A/S Sponsored ADR $GMAB Shares Sold by Mirae Asset Global Investments Co. Ltd.October 13, 2025 | marketbeat.comWilliam Blair Brokers Lift Earnings Estimates for Genmab A/SOctober 13, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Buys New Shares in Genmab A/S Sponsored ADR $GMABOctober 10, 2025 | marketbeat.comQRG Capital Management Inc. Sells 8,945 Shares of Genmab A/S Sponsored ADR $GMABOctober 9, 2025 | marketbeat.comWeiss Ratings Reaffirms Hold (C) Rating for Genmab A/S (NASDAQ:GMAB)October 9, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Sets New 1-Year High - Here's WhyOctober 6, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Upgraded to Strong-Buy at Zacks ResearchOctober 4, 2025 | marketbeat.comWhy Genmab Stock Popped on FridayOctober 3, 2025 | fool.comGenmab price target raised to $40 from $36 at H.C. WainwrightOctober 2, 2025 | msn.comHC Wainwright Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock PriceOctober 2, 2025 | marketbeat.comLeerink Partnrs Comments on Genmab A/S FY2027 EarningsOctober 2, 2025 | marketbeat.comTD Cowen Remains a Hold on Genmab (GMAB)October 2, 2025 | theglobeandmail.comFY2025 EPS Estimates for Genmab A/S Boosted by William BlairOctober 1, 2025 | marketbeat.comGenmab A/S Updates Articles of Association to Enhance Growth StrategySeptember 30, 2025 | msn.comMERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUSSeptember 30, 2025 | businesswire.comGenmab A/S (NASDAQ:GMAB) Sets New 52-Week High - What's Next?September 30, 2025 | marketbeat.comGenmab A/S (GMAB) Merus N.V. - M&A Call - SlideshowSeptember 30, 2025 | seekingalpha.comGenmab A/S (GMAB) M&A Call TranscriptSeptember 29, 2025 | seekingalpha.comGenmab Strikes $8 Billion Deal To Acquire Cancer-Focused MerusSeptember 29, 2025 | msn.comGenmab Makes A Big Bet With Merus N.V. AcquisitionSeptember 29, 2025 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst UpgradeSeptember 29, 2025 | marketbeat.comThis Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.September 29, 2025 | barrons.comGenmab to buy Dutch cancer drugmaker Merus for $8 billionSeptember 29, 2025 | reuters.comGenmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned ModelSeptember 29, 2025 | businesswire.comGenmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned ModelSeptember 29, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by Wall Street ZenSeptember 26, 2025 | marketbeat.comGrant of Restricted Stock Units and Warrants to Employees in GenmabSeptember 25, 2025 | globenewswire.comGenmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeptember 25, 2025 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Sets New 52-Week High Following Analyst UpgradeSeptember 23, 2025 | marketbeat.comMajor Shareholder AnnouncementSeptember 23, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy RatingSeptember 23, 2025 | marketbeat.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 21, 2025 | marketbeat.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.260.48▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼338▲GMAB Articles Average Week Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies argenex News Today Takeda Pharmaceutical News Today BeOne Medicines News Today Insmed News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Ascendis Pharma A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.